Sanofi has placed an enterprise value of €16m ($17m) on Opella, around 14 times the estimated core earnings (EBITDA) for 2024, as per a 21 October press release.

The valuation for Opella is based on an enterprise value of approximately €16 billion, equating to around 14 times its projected EBITDA for 2024. CD&R's offer is binding and fully financed.

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a ...

French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

Sanofi SAN -0.13% is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company’s consumer health business ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a ...

The valuation of Opella is based on an enterprise value of c.€16 billion, corresponding to c.14 times 2024 estimated EBITDA. The offer from CD&R is binding and fully financed.

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to sell a 50% controlling stake of its consumer health business Opella for ...

PARIS, Oct 17 (Reuters) - French drugmaker Sanofi (SASY.PA) said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm Opella from private equity firm PAI Partners, saying ...

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries and manages 13 best-in-class manufacturing sites and four research and innovation centers.

Among the penalties is a €40 million fine if Opella stops making its products at two facilities in Lisieux and Compiègne and €100,000 for each layoff that takes place for economic reasons.

While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees across 100 countries, Sanofi in October proposed a plan to sell a 50% controlling stake to U ...